首页> 美国卫生研究院文献>International Journal of Nanomedicine >A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon specific drug delivery system: an approach to alternative colon media
【2h】

A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon specific drug delivery system: an approach to alternative colon media

机译:一种新型的溶出介质,用于测试基于纳米结构多糖的结肠特异性药物递送系统的药物释放:替代结肠介质的方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was to develop a novel microbially triggered and animal-sparing dissolution method for testing of nanorough polysaccharide-based micron granules for colonic drug delivery. In this method, probiotic cultures of bacteria present in the colonic region were prepared and added to the dissolution media and compared with the performance of conventional dissolution methodologies (such as media with rat cecal and human fecal media). In this study, the predominant species (such as Bacteroides, Bifidobacterium, Lactobacillus species, Eubacterium and Streptococcus) were cultured in 12% w/v skimmed milk powder and 5% w/v grade “A” honey. Approximately 1010–1011 colony forming units m/L of probiotic culture was added to the dissolution media to test the drug release of polysaccharide-based formulations. A USP dissolution apparatus I/II using a gradient pH dissolution method was used to evaluate drug release from formulations meant for colonic drug delivery. Drug release of guar gum/Eudragit FS30D coated 5-fluorouracil granules was assessed under gastric and small intestine conditions within a simulated colonic environment involving fermentation testing with the probiotic culture. The results with the probiotic system were comparable to those obtained from the rat cecal and human fecal-based fermentation model, thereby suggesting that a probiotic dissolution method can be successfully applied for drug release testing of any polysaccharide-based oral formulation meant for colonic delivery. As such, this study significantly adds to the nanostructured biomaterials’ community by elucidating an easier assay for colonic drug delivery.
机译:这项研究的目的是开发一种新的微生物触发的和保留动物的溶出方法,以测试基于纳米粗多糖的微米颗粒用于结肠给药。在这种方法中,准备了存在于结肠区域的细菌的益生菌培养物,并将其添加到溶出介质中,并与常规溶出方法(例如具有大鼠盲肠和人粪便介质的介质)的性能进行了比较。在这项研究中,主要物种(如拟杆菌,双歧杆菌,乳杆菌,真细菌和链球菌)在12%w / v脱脂奶粉和5%w / v“ A”级蜂蜜中培养。将约10 10 –10 11 菌落形成单位m / L的益生菌培养物添加到溶出介质中,以测试基于多糖的制剂的药物释放。使用梯度pH溶出方法的USP溶出仪I / II用于评估药物从打算用于结肠药物递送的制剂中的释放。瓜尔胶/ Eudragit FS30D包被的5-氟尿嘧啶颗粒的药物释放是在模拟结肠环境中,在胃和小肠条件下进行的,包括益生菌培养物的发酵测试。益生菌系统的结果可与基于大鼠盲肠和人粪便的发酵模型获得的结果相媲美,从而表明益生菌溶解方法可成功用于任何用于结肠递送的基于多糖的口服制剂的药物释放测试。因此,这项研究阐明了一种更简便的结肠药物递送测定方法,从而大大增加了纳米结构生物材料的领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号